Altrova Health Reports Third Quarter Fiscal 2026 Financial Results

Toronto, Ontario--(Newsfile Corp. - August 31, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") today announced its financial results for the three and nine-month periods ended June 30, 2026 ("Q3 Fiscal 2026"). The Company's condensed interim consolidated financial statements and related management's discussion and analysis for the period (collectively, the "Interim Filings") have been filed under the Company's profile on SEDAR+ at www.sedarplus.ca. All dollar amounts in this news release are expressed in Canadian dollars unless otherwise indicated.

Q3 Fiscal 2026 Highlights: * First commercial revenue: nine-month revenue of $112,000, up from $15,551 in the prior comparative period, as distribution and commercialization initiatives put in place over the past year began converting into recurring commercial activity for the first time in the Company's history. * Expanding distribution network: continued NIRLAB SA ("NIRLAB") device sales, expanded partnerships with Indigenous and First Nations communities, and a planned relaunch of the Drug Lab 118 Ltd. rapid detection strip portfolio. * Completed rebrand and cross-border uplisting: shares now trade as Altrova Health Inc. on the CSE (ROVA) and OTCQB (ATVHF), aligning the Company's US and Canadian trading identity with its healthcare platform. * Lower discretionary costs: general and administrative, investor relations and professional fees each declined year-over-year even as the Company scaled its commercial operations.